Clinical Trial

Activated Charcoal Use in Chronic Kidney Disease Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT06906874
Lead Sponsor Mansoura University
Conditions End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
Enrollment 40 participants
Start Date 2025-08
Primary Completion 2025-11 (estimated)
Study Completion 2025-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-08